This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Catalog Advanced Search
402 items were found using the following search criteria
-
Flying J (A)
Deshpande, Rohit; Barley, LaurenCase HBS-508074-EMarketingThe largest retailer of diesel fuel in the U.S., Flying J, is rethinking its growth strategy as the economy goes into a recession. Its major customer base, owner-operated truck drivers, are facing increasing costs of doing business. Yet Flying J is considering whether to increase its price of diesel fuel.Starting at €8.20
-
The Flaxil Label (C): Debrief and Endnotes
Barron, GregoryCase HBS-909003-EThis case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite qualitative and differs from the typical price negotiation with which students are familiar. However, at stake was $500 million in Flaxil sales and the safety of millions of patients. The sup...Starting at €5.74
-
Medtronic: Patient Management Initiative (B)
Herzlinger, Regina E.Case HBS-309064-EThe (B) case provides the denouement to the (A) case about Medtronic's introduction of the Chronicle and remote monitoring business.Starting at €5.74
-
Biocon: Launching a New Cancer Drug in India, Teaching Note
Gupta, Sunil; Narayandas, DasTeaching Note HBS-509039-EMarketingTeaching Note for [508026].Starting at €0.00
-
Cleveland Clinic: Transformation and Growth 2015
Porter, Michael E.; Teisberg, Elizabeth OlmstedCase HBS-709473-EStrategyThe Cleveland Clinic's health care services are internationally renowned for quality. In 2008, The Clinic began to restructure the organization into teams defined around patient needs, rather than traditional medical specialties."Patients First! takes shape as the teams measure and report outcomes, coordinate care, and develop to support improving value for patients. In addition to restructuring care delivery in the hospitals and throughout north...Starting at €8.20
-
Examining the Adoption of Drug-Eluting Stents, Teaching Note
Ofek, Elie; Wickersham, PeterTeaching Note HBS-509053-EMarketingTeaching Note for [509028].Starting at €0.00
-
Dr. Benjamin Hooks and Children's Health Forum
Kanter, Rosabeth Moss; Ogletree, Charles J., Jr.; Koh, Howard; Atkinson, Abbye; Salhi, Carmel; Sesia, AldoCase HBS-309111-E"Dr. Benjamin Hooks and Children's Health Forum" charts the many different career paths of Hooks, a civil right activist and pioneer. Hooks' positions ranged from lawyer, judge, preacher, entrepreneur to the first African American commissioner of the Federal Communications Commission (FCC) and to the head of the National Association for the Advancement of Colored People (NAACP) to the co-founder of the non-profit Children's Health Forum (CHF). CH...Starting at €8.20
-
MINTing Innovation at NewYork-Presbyterian (A)
Hamermesh, Richard G.; Kiron, DavidCase HBS-810004-EEntrepreneurshipSeveral top surgeons at NewYork-Presbyterian hospital (NYP) are receiving financial and administrative support to advance their surgical device inventions through the earliest stages of commercialization.Starting at €8.20
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCase HBS-810027-EEntrepreneurshipNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Starting at €8.20
-
Gilead Sciences, Inc.: Access Program
Rangan, V. Kasturi; Lee, KatharineCase HBS-510029-EStrategyTo maximize their effectiveness, color cases should be printed in color. Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients by the middle of 2009, the company's senior managers contemplated how to reach 2 million patients by 2012.Starting at €8.20